Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid
Cockbain AJ, Volpato M, Race AD, Munarini A, Fazio C, Belluzzi A, Loadman PM, Toogood GJ, Hull MA
Gut · 94 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Cancer Research UK
- Gobierno
- National Institute for Health and Care Research
- Gobierno
- Medical Research Council
- Gobierno
- National Institute for Health Research (NIHR)
Según 4 financiadores declarados.
Publicación
- Publicado
- 2014-01-27 · Gut · vol. 63 · número 11 · págs. 1760–1768
- Editorial
- BMJ
- Citado
- 113 citas · más que el 98% de estudios similares · 8.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 33 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Cancer, Lipids, and Metabolism · Colorectal Cancer Treatments and Studies
- Palabras clave
- eicosapentaenoic acid, omega-3 fatty acids, colorectal liver metastases, hepatectomy, antiangiogenic activity, tumor vascularity, Ki-67 proliferation index, overall survival, disease-free survival, tolerability
- MeSH
- humans, colorectal neoplasms, liver neoplasms, eicosapentaenoic acid, anticarcinogenic agents, chromatography, liquid, immunohistochemistry, double-blind method, adult, aged, aged, 80 and over, middle aged, female, male, tandem mass spectrometry, platelet endothelial cell adhesion molecule-1
9 autores
- Andrew J. Cockbain🇬🇧Leeds Teaching Hospitals NHS Trust; St James's University Hospital
- Milène Volpato🇬🇧St James's University Hospital
- Amanda D. Race🇬🇧University of Bradford
- Alessandra Munarini🇮🇹IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola; University of Bologna
- Chiara Fazio🇮🇹IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola; University of Bologna
- Andrea Belluzzi🇮🇹IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola; University of Bologna
- Paul M. Loadman🇬🇧University of Bradford
- Giles J. Toogood🇬🇧Leeds Teaching Hospitals NHS Trust; St James's University Hospital
- Mark A. Hull🇬🇧 · autor de correspondenciaSt James's University Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Oral administration of the omega-3 fatty acid eicosapentaenoic acid (EPA), as the free fatty acid (FFA), leads to EPA incorporation into, and reduced growth of, experimental colorectal cancer liver metastases (CRCLM).
Design
We performed a Phase II double-blind, randomised, placebo-controlled trial of EPA-FFA 2 g daily in patients undergoing liver resection surgery for CRCLM. The patients took EPA-FFA (n=43) or placebo (n=45) prior to surgery. The primary end-point was the CRCLM Ki67 proliferation index (PI). Secondary end-points included safety and tolerability of EPA-FFA, tumour fatty acid content and CD31-positive vascularity. We also analysed overall survival (OS) and disease-free survival (DFS).
Results
The median (range) duration of EPA-FFA treatment was 30 (12-65) days. Treatment groups were well matched with no significant difference in disease burden at surgery or preoperative chemotherapy. EPA-FFA treatment was well tolerated with no excess of postoperative complications. Tumour tissue from EPA-FFA-treated patients demonstrated a 40% increase in EPA content (p=0.0008), no difference in Ki67 PI, but reduced vascularity in 'EPA-naïve' individuals (p=0.075). EPA-FFA also demonstrated antiangiogenic activity in vitro. In the first 18 months after CRCLM resection, EPA-FFA-treated individuals obtained OS benefit compared with placebo, although early CRC recurrence rates were similar.
Conclusions
EPA-FFA therapy is safe and well tolerated in patients with advanced CRC undergoing liver surgery. EPA-FFA may have antiangiogenic properties. Remarkably, limited preoperative treatment may provide postoperative OS benefit. Phase III clinical evaluation of prolonged EPA-FFA treatment in CRCLM patients is warranted.
Trial identifier
ClinicalTrials.gov NCT01070355.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.